The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
NCRI 2019 | HER-2 conversion: a phenomenon in trastuzumab resistance
Russell Petty, BMSC, MB ChB, PhD, MRCP, University of Dundee, Dundee, UK, talks about precision cancer biology and the phenomenon of HER-2 conversion that occurs in trastuzumab resistance. Recorded at the 2019 National Cancer Research Institute (NCRI) Annual Cancer Conference, in Glasgow, UK.
For more information about the NCRI Cancer Conference, visit https://conference.ncri.org.uk.
